If you're a long-term investor, why should you be paying closer attention to pharmaceutical giant Pfizer (NYSE: PFE)? Because ...

Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum. Click here to ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup.

Pfizer has an attractive 7.2% dividend yield, but this healthcare giant might be a riskier dividend stock than you want to ...

Pfizer faces a significant patent cliff, pricing reforms, and limited financial flexibility from high debt, all threatening ...

In the most recent trading session, Pfizer (PFE) closed at $24.83, indicating a +1.04% shift from the previous trading day.

Pfizer's stock is down nearly 60% from its post-pandemic peak, opening up an opportunity for the right long-term investors.

This drop brings the stock's year-to-date decline to almost 45%. A key question now is how MRNA's performance compares to ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

AbbVie is a Dividend King that should hold up better than most during a stock market sell-off. Enterprise Products Partners ...

The Zacks Consensus Estimate for Pfizer’s 2025 sales and EPS implies a year-over-year increase of 0.3% and 1.0%, respectively ...

Pfizer Inc. (NYSE:PFE) ranks among the world’s top pharmaceutical companies, with vast resources to back its research and ...